CAT-354, an IL-13-neutralising human monoclonal antibody, inhibits airways hyperresponsiveness and eosinophilia in a cynomolgus monkey model of allergen challenge Source: Eur Respir J 2005; 26: Suppl. 49, 232s Year: 2005
Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Induction of allergic bronchial hyperreactivity in DA-rats despite low-level eosinophilia in airways and lack of specific IgE antibodies Source: Annual Congress 2007 - Mouse models of allergic airway inflammation Year: 2007
Early Ascaris suum migration in mice induces eosinophils airway inflammation and hyperresponsiveness Source: Eur Respir J 2005; 26: Suppl. 49, 587s Year: 2005
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020
Changes in total and specific IgE following treatment with mebendazole in patients with persistent asthma and IgE to Ascaris lumbricoides Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Anti-IL-5 antibody reduces the increase of CD34+ eosinophils in a mouse model of airway allergic eosinophilia Source: Eur Respir J 2002; 20: Suppl. 38, 28s Year: 2002
Subcutaneuous injection of monoclonal antibody anti-DEC205 conjugated with ovalbumin atenuates allergic lung inflammation of animals previously sensitized to allergen Source: Annual Congress 2012 - Mechanisms and modulation of allergic inflammation in the lung Year: 2012
Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001
The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
Endotoxin potentiates allergic airway inflammation in ovalbumin sensitised and challenged mice Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001
A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006
Intratracheal instillation of antigen-specific IgG ameliorated murine bronchial asthma via reduction of antigen presentation of airway dendritic cells Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008
Omalizumab inhibits allergen challenge-induced nasal response Source: Eur Respir J 2004; 23: 414-419 Year: 2004
Comparison of anti-IL-9 and anti-IL-5 treatment efficacy in a mouse model of airway eosinophilic inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 482s Year: 2003
Aerobic conditioning inhibits ovalbumin allergic sensitisation and airway inflammation in mice Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009